Global Oncology Industry Market Research & Statistics

PharmaPoint: Prostate Cancer - Global Drug Forecast and ... $ 10995 November 2017

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026SummaryProstate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of ...

PharmaPoint: Macular Edema - Global Drug Forecast and M ... $ 10995 November 2017

PharmaPoint: Macular Edema - Global Drug Forecast and Market Analysis to 2026SummaryMacular edema (ME) is a condition where fluid and protein deposits accumulate on the macula, causing it to swell, leading ...

PharmaPoint: Melanoma - Global Drug Forecast and Market ... $ 10995 September 2017

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026SummaryMelanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared to other major cancer indications, ...

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportuni ... $ 10995 July 2017

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026SummaryAcute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively ...

PharmaPoint: HER2-Positive Breast Cancer - Global Drug ... $ 10995 June 2017

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025SummaryHER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

OpportunityAnalyzer: Bladder Cancer - Opportunity Analy ... $ 10995 April 2017

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025SummaryBladder cancer is a urologic malignancy arising primarily from epithelial cells lining the bladder. In the vast majority ...

Drug Analysis: Ofatumumab $ 10000 November 2017

Drug OverviewOfatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumuma ...

Targeted Therapies in Asthma: KOL Insight [2018] $ 8685 February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

PharmaFocus: Visual Analysis of Immuno-Oncology Develop ... $ 7995 August 2017

PharmaFocus: Visual Analysis of Immuno-Oncology Development and OpportunitiesSummaryImmuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, ...